(Q39414529)

English

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

scientific article published on October 2001

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

irritable bowel syndrome

1 reference

based on heuristic

inferred from title

author name string

Müller-Lissner SA

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Fumagalli I

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Bardhan KD

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Pace F

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Pecher E

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Nault B

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Rüegg P

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

1 October 2001

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1655-1666

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Review article: irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Irritable bowel syndrome in office-based practice in the United States

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Symptom differences in moderate to severe IBS patients based on predominant bowel habit

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of Agonists

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Irritable bowel syndrome clinical trial design: future needs

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Colonic motility in humans--a growing understanding

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Treatment of chronic constipation with cisapride and placebo

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Long QT Syndrome During High-Dose Cisapride

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2001.01094.X

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39414529&oldid=1826527234"